ATE322264T1 - Medizinische zusammensetzungen als begleittherapie gegen krebs - Google Patents
Medizinische zusammensetzungen als begleittherapie gegen krebsInfo
- Publication number
- ATE322264T1 ATE322264T1 AT01978983T AT01978983T ATE322264T1 AT E322264 T1 ATE322264 T1 AT E322264T1 AT 01978983 T AT01978983 T AT 01978983T AT 01978983 T AT01978983 T AT 01978983T AT E322264 T1 ATE322264 T1 AT E322264T1
- Authority
- AT
- Austria
- Prior art keywords
- ring
- salt
- substituent group
- companionary
- against cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- -1 sulfonamide compound Chemical class 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 abstract 1
- 229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000333952 | 2000-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322264T1 true ATE322264T1 (de) | 2006-04-15 |
Family
ID=18809950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01978983T ATE322264T1 (de) | 2000-10-31 | 2001-10-31 | Medizinische zusammensetzungen als begleittherapie gegen krebs |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20040002505A1 (de) |
| EP (1) | EP1331005B1 (de) |
| JP (1) | JP4167898B2 (de) |
| KR (1) | KR100829875B1 (de) |
| CN (1) | CN1196484C (de) |
| AT (1) | ATE322264T1 (de) |
| AU (2) | AU1099302A (de) |
| CA (1) | CA2427617C (de) |
| DE (1) | DE60118590T2 (de) |
| NZ (1) | NZ524975A (de) |
| TW (1) | TWI283575B (de) |
| WO (1) | WO2002036117A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| EP1604665B1 (de) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| DE602004010900D1 (de) * | 2003-05-08 | 2008-02-07 | Eisai R&D Man Co Ltd | Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika |
| JP4418430B2 (ja) * | 2003-09-10 | 2010-02-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド含有インドール化合物の製造方法 |
| MXPA06002732A (es) * | 2003-09-10 | 2006-06-05 | Eisai Co Ltd | Compuesto de indol que contiene sulfonamida cristalina y proceso para su preparacion. |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| NZ548212A (en) * | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| CA2557504C (en) * | 2004-02-26 | 2020-12-01 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| JP5106098B2 (ja) * | 2005-02-28 | 2012-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の抗癌剤との新規併用 |
| CN1313104C (zh) * | 2005-05-27 | 2007-05-02 | 中国科学院南海海洋研究所 | 一种具有柴胡和多霉素协同作用的抗癌药物组合物 |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| KR101294014B1 (ko) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| US8053603B2 (en) * | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| CN104706637A (zh) * | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| US20080058395A1 (en) * | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| US20090099248A1 (en) * | 2007-01-18 | 2009-04-16 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| CA2704000C (en) * | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2011017634A2 (en) * | 2009-08-07 | 2011-02-10 | Sepracore Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US10143657B2 (en) | 2014-01-17 | 2018-12-04 | Oncoral Pharma Aps | Solid oral dosage form of irinotecan for the treatment of cancer |
| EP3187491A4 (de) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | Hochreines chinolinderivat und verfahren zur herstellung davon |
| AU2015360761B2 (en) * | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| EP3791876A1 (de) | 2015-08-21 | 2021-03-17 | Ipsen Biopharm Ltd. | Verfahren zur behandlung von metastasierendem bauchspeicheldrüsenkrebs mithilfe von kombinationstherapien mt liposomalem irinotecan und oxaliplatin |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| RU2121997C1 (ru) * | 1993-09-10 | 1998-11-20 | Эйсай Ко., ЛТД | Производные 7-амино-1н-индола |
| JPH09208571A (ja) * | 1996-02-02 | 1997-08-12 | Takeda Chem Ind Ltd | アルキリデンシクロヘキサン誘導体 |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| US6911306B1 (en) * | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
| EP1296714B1 (de) * | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
-
2001
- 2001-10-30 TW TW090126893A patent/TWI283575B/zh active
- 2001-10-31 CA CA002427617A patent/CA2427617C/en not_active Expired - Fee Related
- 2001-10-31 DE DE60118590T patent/DE60118590T2/de not_active Expired - Lifetime
- 2001-10-31 WO PCT/JP2001/009563 patent/WO2002036117A1/ja not_active Ceased
- 2001-10-31 JP JP2002538929A patent/JP4167898B2/ja not_active Expired - Fee Related
- 2001-10-31 US US10/381,909 patent/US20040002505A1/en not_active Abandoned
- 2001-10-31 CN CNB018183581A patent/CN1196484C/zh not_active Expired - Fee Related
- 2001-10-31 AT AT01978983T patent/ATE322264T1/de not_active IP Right Cessation
- 2001-10-31 AU AU1099302A patent/AU1099302A/xx active Pending
- 2001-10-31 AU AU2002210993A patent/AU2002210993B2/en not_active Ceased
- 2001-10-31 NZ NZ524975A patent/NZ524975A/en unknown
- 2001-10-31 EP EP01978983A patent/EP1331005B1/de not_active Expired - Lifetime
- 2001-10-31 KR KR1020037004463A patent/KR100829875B1/ko not_active Expired - Fee Related
-
2003
- 2003-05-08 US US10/431,569 patent/US20030215523A1/en not_active Abandoned
-
2004
- 2004-05-06 US US10/839,222 patent/US20040224972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR100829875B1 (ko) | 2008-05-16 |
| US20030215523A1 (en) | 2003-11-20 |
| CN1473041A (zh) | 2004-02-04 |
| JP4167898B2 (ja) | 2008-10-22 |
| DE60118590D1 (de) | 2006-05-18 |
| EP1331005A4 (de) | 2004-12-22 |
| AU1099302A (en) | 2002-05-15 |
| CA2427617A1 (en) | 2003-04-29 |
| NZ524975A (en) | 2004-11-26 |
| DE60118590T2 (de) | 2007-01-18 |
| WO2002036117A1 (en) | 2002-05-10 |
| JPWO2002036117A1 (ja) | 2004-03-11 |
| US20040002505A1 (en) | 2004-01-01 |
| TWI283575B (en) | 2007-07-11 |
| CN1196484C (zh) | 2005-04-13 |
| AU2002210993B2 (en) | 2006-12-07 |
| EP1331005A1 (de) | 2003-07-30 |
| KR20030046475A (ko) | 2003-06-12 |
| US20040224972A1 (en) | 2004-11-11 |
| EP1331005B1 (de) | 2006-04-05 |
| CA2427617C (en) | 2009-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60118590D1 (de) | Medizinische zusammensetzungen als begleittherapie gegen krebs | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| DE60227794D1 (de) | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| SE0102764D0 (sv) | Compounds | |
| DE60118225D1 (de) | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| DE60330407D1 (de) | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung | |
| DE60115465D1 (de) | Immunoregulierende verbindungen, deren derivate und ihre verwendung | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| ATE450499T1 (de) | Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten | |
| BRPI0417007A (pt) | agentes antivirais de diazaindol-dicarbonil-piperazinila | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| BR0214842A (pt) | Inibidores de integrase hiv | |
| PT1251846E (pt) | Taxanos com carbonato c-4 | |
| NO20025035D0 (no) | Oksadiazolderivater som har anticancer-effekter | |
| EE200000472A (et) | Kasvajavastased toimeained | |
| NO20032261D0 (no) | Medisinske preparater | |
| FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
| CA2535210A1 (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| BR9807330A (pt) | Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo | |
| ATE325116T1 (de) | Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate | |
| DE60222591D1 (de) | Oberflächenaktive Verbindungen und ihre Anwendungen | |
| KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |